- Home
- SRV vs CDXS Comparison
SRV vs CDXS Comparison
Compare SRV & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- CDXS
- Stock Information
- Founded
- SRV 2007
- CDXS 2002
- Country
- SRV United States
- CDXS United States
- Employees
- SRV N/A
- CDXS N/A
- Industry
- SRV Finance Companies
- CDXS Major Chemicals
- Sector
- SRV Finance
- CDXS Industrials
- Exchange
- SRV Nasdaq
- CDXS Nasdaq
- Market Cap
- SRV 193.1M
- CDXS 216.6M
- IPO Year
- SRV N/A
- CDXS 2010
- Fundamental
- Price
- SRV $43.02
- CDXS $2.59
- Analyst Decision
- SRV
- CDXS Buy
- Analyst Count
- SRV 0
- CDXS 2
- Target Price
- SRV N/A
- CDXS $11.00
- AVG Volume (30 Days)
- SRV 33.9K
- CDXS 549.5K
- Earning Date
- SRV 01-01-0001
- CDXS 11-06-2025
- Dividend Yield
- SRV 13.38%
- CDXS N/A
- EPS Growth
- SRV N/A
- CDXS N/A
- EPS
- SRV N/A
- CDXS N/A
- Revenue
- SRV N/A
- CDXS $57,164,000.00
- Revenue This Year
- SRV N/A
- CDXS $12.88
- Revenue Next Year
- SRV N/A
- CDXS $21.64
- P/E Ratio
- SRV N/A
- CDXS N/A
- Revenue Growth
- SRV N/A
- CDXS N/A
- 52 Week Low
- SRV $30.73
- CDXS $1.90
- 52 Week High
- SRV $44.30
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- SRV 45.22
- CDXS 48.68
- Support Level
- SRV $42.00
- CDXS $2.55
- Resistance Level
- SRV $42.81
- CDXS $2.80
- Average True Range (ATR)
- SRV 0.89
- CDXS 0.16
- MACD
- SRV -0.07
- CDXS -0.01
- Stochastic Oscillator
- SRV 39.26
- CDXS 25.27
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.